Alvotech Stock Plummets to New 52-Week Low of $3.65

Alvotech, a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 3.65 on March 3, 2026. This significant drop highlights the company's ongoing struggles, as it has experienced a staggering 73.72% decline over the past year, contrasting sharply with the S&P 500's positive performance of 17.36% during the same period. The company's market capitalization stands at USD 1,238 million, and it currently has a price-to-earnings (P/E) ratio of 41.00. However, Alvotech's financial metrics reveal challenges, including a negative book value and a return on equity of -39.32%. The company has not paid dividends, and its debt-to-equity ratio is reported at -6.19, indicating potential difficulties in managing its financial obligations. Despite a notable annual growth rate in net sales of 256.02% and operating profit growth of 37.21% over the last five years, Alvotech's ability to service its debt remains weak, as evidenced by an average EBIT to interest ratio of -7.56. The stock's performance has consistently underperformed against the S&P 500 over the last three years, raising concerns about its long-term viability in the competitive biotechnology landscape.